Literature DB >> 12485605

Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation.

Jong K Yun1, Mark Kester.   

Abstract

Vascular cell adaptive response to hypoxic stress includes enhanced production of sphingomyelin metabolites that regulate cell growth. Here, we examined the vascular smooth muscle (VSM) cell adaptive response to hypoxia (2 and 5% O(2)) and demonstrated that acute (</=16h) hypoxic stress significantly stimulated VSM cell growth compared to cells grown under normoxic (21% O(2)) conditions. This stimulatory effect of hypoxia on VSM cell growth was significantly inhibited by pretreatment of cells with D-erythro-N,N-dimethylsphingosine, an inhibitor of sphingosine kinase. These results suggest a mechanism by which sphingosine 1-phosphate (S-1-P), a promitogenic sphingolipid-derived second messenger, may play a key role in hypoxia-induced VSM cell growth. Supporting this, S-1-P formation was significantly increased in VSM cells subjected to hypoxia. The hypoxia-induced increase in S-1-P level correlated with the decrease in total cellular ceramide content, a sphingolipid metabolite associated with inhibition of cell growth. The activity of sphingomyelinase was also significantly inhibited in hypoxia-treated VSM cells, likely further contributing to a decrease in total intracellular content of ceramide. As a decrease in ceramide content may play a role in hypoxia-induced VSM growth, we next examined the effects of ceramide in VSM cell growth. Elevating intracellular ceramide content through exogenous (C(6)-ceramide) or endogenous (ceramidase inhibition) manipulations led to a decrease in hypoxia-induced VSM cell growth. In contrast, hypoxia-induced VSM cell growth was further enhanced by S-1-P treatment. Together, our study indicates that hypoxia-induced VSM cell growth may be modulated by sphingomyelin metabolism that results in reduction of total intracellular ceramide level with concomitant increase in S-1-P formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12485605     DOI: 10.1016/s0003-9861(02)00526-x

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

1.  Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide.

Authors:  Yan Sun; Todd Fox; Gautam Adhikary; Mark Kester; Eric Pearlman
Journal:  J Leukoc Biol       Date:  2008-04-17       Impact factor: 4.962

2.  Distribution of sphingosine kinase activity and mRNA in rodent brain.

Authors:  Nicolas Blondeau; Yushuan Lai; Sarah Tyndall; Margherita Popolo; Kamil Topalkara; James K Pru; Ling Zhang; Hyunghwan Kim; James K Liao; Kan Ding; Christian Waeber
Journal:  J Neurochem       Date:  2007-07-10       Impact factor: 5.372

Review 3.  Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertension.

Authors:  Xi-Qian Xing; Yan-Li Li; Yu-Xuan Zhang; Yi Xiao; Zhi-Dong Li; Li-Qiong Liu; Yu-Shan Zhou; Hong-Yan Zhang; Yan-Hong Liu; Li-Hui Zhang; Min Zhuang; Yan-Ping Chen; Sheng-Rong Ouyang; Xu-Wei Wu; Jiao Yang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells.

Authors:  Seon-Ok Lee; Joo-Seok Kim; Myoung-Sun Lee; Hyo-Jeong Lee
Journal:  BMC Cancer       Date:  2016-08-31       Impact factor: 4.430

Review 5.  Ceramide in stress response.

Authors:  Mariana N Nikolova-Karakashian; Krassimira A Rozenova
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 6.  Sphingolipids in Obesity and Correlated Co-Morbidities: The Contribution of Gender, Age and Environment.

Authors:  Enrica Torretta; Pietro Barbacini; Nasser M Al-Daghri; Cecilia Gelfi
Journal:  Int J Mol Sci       Date:  2019-11-24       Impact factor: 5.923

7.  Metabonomic analysis of abnormal sphingolipid metabolism in rheumatoid arthritis synovial fibroblasts in hypoxia microenvironment and intervention of geniposide.

Authors:  Jiang-Tao Ke; Heng Zhang; Yan-Hong Bu; Pei-Rong Gan; Fang-Yuan Chen; Xin-Tong Dong; Yan Wang; Hong Wu
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

Review 8.  Ceramide and Ischemia/Reperfusion Injury.

Authors:  Xingxuan He; Edward H Schuchman
Journal:  J Lipids       Date:  2018-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.